CMPS Crashes 27% as Earnings Loom and Analysts Trim

COMPASS Pathways heads into tomorrow's results with the stock down 27% on the week, analysts cutting targets, and the market scrambling to reprice a thesis that looked very different a month ago.

The magnitude of the sell-off this week is the defining fact right now. The stock closed at $8.59 on Tuesday, down 27% in five sessions and down a similar amount over the past month. A partial recovery of 2.1% on Tuesday barely registers against that drawdown. Earnings are scheduled for November 5, and the market is clearly arriving at that event in a very different mood than it was in October. The last comparable earnings release, in August, sent the stock up 14.8% the following day and 20.5% over the subsequent week. That reaction suggests the binary character of this stock is well established, which makes the current positioning worth reading carefully.

The lending market tells a story of pressure easing rather than building. Availability has risen sharply over the past week, up 42% to 392%, meaning there are roughly four shares available to borrow for every one already on loan. That is loose by any measure. Borrowing costs have also fallen 15% over the week to around 0.5%. Short interest has nudged down about 1.5% over the week, though it remains 13% above its level a month ago. The ORTEX short score, which integrates short positioning, momentum, and borrow dynamics, has also been declining steadily, dropping from above 70 at the end of October to 65.4 on November 3. The lending market is not signalling an imminent squeeze. If anything, shorts have been modestly covering into the decline, with the borrow pool loosening as the stock fell.

Options positioning has shifted more defensive, though not dramatically so. The put/call ratio moved up to 0.37, running above its 20-day average of 0.31 by roughly 1.3 standard deviations. That is elevated relative to recent norms but nowhere near the 52-week high of 1.38. The options market is adding some downside protection ahead of the print, but not at panic levels.

The analyst picture is split in a way that captures the stock's fundamental ambiguity. Wells Fargo cut its target from $13 to $10 on November 4 while holding its Equal-Weight rating, the first move following the results announcement. BTIG reiterated Buy at $25 on November 3. The divide between those two positions, $10 versus $25, reflects a genuine disagreement about FDA approval probability and commercial execution rather than a minor difference in modelling assumptions. The bull case rests on COMP360's rolling NDA, its Phase 3 durability data, over 8,000 potential clinic sites in the commercial footprint, and $433 million of cash runway into 2028. The bear case focuses on binary trial risk, regulatory and insurance uncertainty, and the dilution threat that comes with a single-asset, pre-revenue biotech. The mean analyst price target from recent actionable moves sits in the low-to-mid twenties, against a current price of $8.59, implying substantial implied upside. Given the gap, the stock's behaviour will almost entirely depend on what management says about the regulatory path rather than near-term financials.

The activist register adds another layer of complexity that is worth carrying. ATAI Life Sciences filed a Schedule 13D/A and holds approximately 6% of the company, down from 7.5% at the previous filing. AtaiBeckley, a related entity, filed its own 13D disclosing a stake just below 5%. Schedule 13D filings denote disclosed activist intent, and ATAI's position has been declining. Per standard disclosure rules, stakes are as-last-filed around the 5% threshold, and a holder who falls below 5% may not file again. BIT Capital filed a fresh 13G in late October disclosing a 5.9% passive stake, an institutional name building in quietly as the stock pulled back.

The next 24 hours are entirely about the COMP360 programme update, specifically whether management provides any new colour on the FDA timeline, the label, and DEA scheduling. Those three items, more than any financial line, will determine whether the stock retraces toward the mid-teens or tests new lows.